Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Leukemia, Myeloid, Acute 2Leukemia 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

fludarabine phosphate 29ruxolitinib 28Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 25Busulfan 21Tacrolimus 16Whole-Body Irradiation 15Mycophenolic Acid 14Methotrexate 13Cyclosporine 12Hydroxyurea 11Antilymphocyte Serum 11Aspirin 9fludarabine 8Filgrastim 8Melphalan 7Etoposide 7Decitabine 7peginterferon alfa-2a 6Imatinib Mesylate 6Cytarabine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6givinostat hydrochloride 5givinostat 5Radiotherapy 5Prednisone 5Carboplatin 5Biopsy 5Topotecan 4Thiotepa 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Polycythemia Vera × lestaurtinib × Clear all
NCT00586651 2015-10-08

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
39 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT00668421 2014-11-26

CEP-701 (Lestaurtinib) in Myelofibrosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Unknown
60 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡